Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
DocMorris ( (CH:DOCM) ) just unveiled an update.
DocMorris reported robust first-quarter 2026 momentum, with external sales up 10.7% in local currency to CHF 318.1 million and consolidated sales rising 11.7%, driven by strong German market performance. Prescription drug revenue surged 30.4%, non-prescription sales grew 6.5%, and Digital Services revenue jumped 63.1%, while the active customer base expanded by 1 million to 12.6 million.
Profitability also improved meaningfully, as adjusted EBITDA narrowed to a loss of CHF 6.3 million, an improvement of CHF 9.8 million from a year earlier, reflecting tighter marketing and cost discipline. Management reaffirmed its 2026 guidance, signaling confidence in reaching EBITDA break-even during 2026 and free cash flow break-even in 2027, underscoring DocMorris’s progress toward sustainable, profitable growth in digital health.
The most recent analyst rating on (CH:DOCM) stock is a Sell with a CHF3.50 price target. To see the full list of analyst forecasts on DocMorris stock, see the CH:DOCM Stock Forecast page.
More about DocMorris
DocMorris AG is a Swiss-listed digital health company focused on online pharmacy, telemedicine and health-product marketplaces, with core operations in Germany and other European markets. The group delivers mainly via a highly automated logistics center in Heerlen, Netherlands, and operates TeleClinic, Germany’s largest telemedicine platform, alongside health and care marketplaces in Southern Europe.
Average Trading Volume: 288,501
Technical Sentiment Signal: Sell
Current Market Cap: CHF270.8M
Find detailed analytics on DOCM stock on TipRanks’ Stock Analysis page.